238 related articles for article (PubMed ID: 24633813)
1. Mitochondrial membrane fluidity is consistently increased in different models of Huntington disease: restorative effects of olesoxime.
Eckmann J; Clemens LE; Eckert SH; Hagl S; Yu-Taeger L; Bordet T; Pruss RM; Muller WE; Leuner K; Nguyen HP; Eckert GP
Mol Neurobiol; 2014 Aug; 50(1):107-18. PubMed ID: 24633813
[TBL] [Abstract][Full Text] [Related]
2. Olesoxime suppresses calpain activation and mutant huntingtin fragmentation in the BACHD rat.
Clemens LE; Weber JJ; Wlodkowski TT; Yu-Taeger L; Michaud M; Calaminus C; Eckert SH; Gaca J; Weiss A; Magg JC; Jansson EK; Eckert GP; Pichler BJ; Bordet T; Pruss RM; Riess O; Nguyen HP
Brain; 2015 Dec; 138(Pt 12):3632-53. PubMed ID: 26490331
[TBL] [Abstract][Full Text] [Related]
3. Differential proteomic and genomic profiling of mouse striatal cell model of Huntington's disease and control; probable implications to the disease biology.
Choudhury KR; Das S; Bhattacharyya NP
J Proteomics; 2016 Jan; 132():155-66. PubMed ID: 26581643
[TBL] [Abstract][Full Text] [Related]
4. Olesoxime improves cerebral mitochondrial dysfunction and enhances Aβ levels in preclinical models of Alzheimer's disease.
Eckert GP; Eckert SH; Eckmann J; Hagl S; Muller WE; Friedland K
Exp Neurol; 2020 Jul; 329():113286. PubMed ID: 32199815
[TBL] [Abstract][Full Text] [Related]
5. Impaired mitochondrial dynamics and Nrf2 signaling contribute to compromised responses to oxidative stress in striatal cells expressing full-length mutant huntingtin.
Jin YN; Yu YV; Gundemir S; Jo C; Cui M; Tieu K; Johnson GV
PLoS One; 2013; 8(3):e57932. PubMed ID: 23469253
[TBL] [Abstract][Full Text] [Related]
6. Olesoxime in neurodegenerative diseases: Scrutinising a promising drug candidate.
Weber JJ; Clemensson LE; Schiöth HB; Nguyen HP
Biochem Pharmacol; 2019 Oct; 168():305-318. PubMed ID: 31283931
[TBL] [Abstract][Full Text] [Related]
7. Mitochondrial modulators improve lipid composition and attenuate memory deficits in experimental model of Huntington's disease.
Mehrotra A; Sood A; Sandhir R
Mol Cell Biochem; 2015 Dec; 410(1-2):281-92. PubMed ID: 26374445
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-124 targets CCNA2 and regulates cell cycle in STHdh(Q111)/Hdh(Q111) cells.
Das E; Jana NR; Bhattacharyya NP
Biochem Biophys Res Commun; 2013 Jul; 437(2):217-24. PubMed ID: 23796713
[TBL] [Abstract][Full Text] [Related]
9. Increased 90-kDa ribosomal S6 kinase (Rsk) activity is protective against mutant huntingtin toxicity.
Xifró X; Anglada-Huguet M; Rué L; Saavedra A; Pérez-Navarro E; Alberch J
Mol Neurodegener; 2011 Oct; 6():74. PubMed ID: 22041125
[TBL] [Abstract][Full Text] [Related]
10. Metabolic state determines sensitivity to cellular stress in Huntington disease: normalization by activation of PPARγ.
Jin YN; Hwang WY; Jo C; Johnson GV
PLoS One; 2012; 7(1):e30406. PubMed ID: 22276192
[TBL] [Abstract][Full Text] [Related]
11. Delayed Cell Cycle Progression in STHdh(Q111)/Hdh(Q111) Cells, a Cell Model for Huntington's Disease Mediated by microRNA-19a, microRNA-146a and microRNA-432.
Das E; Jana NR; Bhattacharyya NP
Microrna; 2015; 4(2):86-100. PubMed ID: 26165466
[TBL] [Abstract][Full Text] [Related]
12. Amitriptyline improves motor function via enhanced neurotrophin signaling and mitochondrial functions in the murine N171-82Q Huntington disease model.
Cong WN; Chadwick W; Wang R; Daimon CM; Cai H; Amma J; Wood WH; Becker KG; Martin B; Maudsley S
J Biol Chem; 2015 Jan; 290(5):2728-43. PubMed ID: 25505248
[TBL] [Abstract][Full Text] [Related]
13. Olesoxime, a cholesterol-like neuroprotectant for the potential treatment of amyotrophic lateral sclerosis.
Martin LJ
IDrugs; 2010 Aug; 13(8):568-80. PubMed ID: 20721828
[TBL] [Abstract][Full Text] [Related]
14. N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking.
Orr AL; Li S; Wang CE; Li H; Wang J; Rong J; Xu X; Mastroberardino PG; Greenamyre JT; Li XJ
J Neurosci; 2008 Mar; 28(11):2783-92. PubMed ID: 18337408
[TBL] [Abstract][Full Text] [Related]
15. Small molecule modulator of protein disulfide isomerase attenuates mutant huntingtin toxicity and inhibits endoplasmic reticulum stress in a mouse model of Huntington's disease.
Zhou X; Li G; Kaplan A; Gaschler MM; Zhang X; Hou Z; Jiang M; Zott R; Cremers S; Stockwell BR; Duan W
Hum Mol Genet; 2018 May; 27(9):1545-1555. PubMed ID: 29462355
[TBL] [Abstract][Full Text] [Related]
16. The calpain-suppressing effects of olesoxime in Huntington's disease.
Weber JJ; Ortiz Rios MM; Riess O; Clemens LE; Nguyen HP
Rare Dis; 2016; 4(1):e1153778. PubMed ID: 27141414
[TBL] [Abstract][Full Text] [Related]
17. Drp1/Fis1-mediated mitochondrial fragmentation leads to lysosomal dysfunction in cardiac models of Huntington's disease.
Joshi AU; Ebert AE; Haileselassie B; Mochly-Rosen D
J Mol Cell Cardiol; 2019 Feb; 127():125-133. PubMed ID: 30550751
[TBL] [Abstract][Full Text] [Related]
18. Striatal neurons expressing full-length mutant huntingtin exhibit decreased N-cadherin and altered neuritogenesis.
Reis SA; Thompson MN; Lee JM; Fossale E; Kim HH; Liao JK; Moskowitz MA; Shaw SY; Dong L; Haggarty SJ; MacDonald ME; Seong IS
Hum Mol Genet; 2011 Jun; 20(12):2344-55. PubMed ID: 21447599
[TBL] [Abstract][Full Text] [Related]
19. RTP801 Is Involved in Mutant Huntingtin-Induced Cell Death.
Martín-Flores N; Romaní-Aumedes J; Rué L; Canal M; Sanders P; Straccia M; Allen ND; Alberch J; Canals JM; Pérez-Navarro E; Malagelada C
Mol Neurobiol; 2016 Jul; 53(5):2857-2868. PubMed ID: 25876513
[TBL] [Abstract][Full Text] [Related]
20. PINK1-induced mitophagy promotes neuroprotection in Huntington's disease.
Khalil B; El Fissi N; Aouane A; Cabirol-Pol MJ; Rival T; Liévens JC
Cell Death Dis; 2015 Jan; 6(1):e1617. PubMed ID: 25611391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
